evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,514 questions · 1,543 findings · 649 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 224 · 14.5%GRADE not reported 105 · 6.8%Very low 383 · 24.8%Low 447 · 29%Moderate 293 · 19%High 91 · 5.9%

Brivaracetam vs placebo

Adverse events as N of participants with at least one adverse event objective · people with drug‐resistant focal epilepsy

Brivaracetam showed no clear difference in proportion of participants who experienced any adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Plerixafor vs placebo

Adverse events (during stem cell mobilisation and collection) · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma

Plerixafor showed no clear difference in adverse events (during stem cell mobilisation and collection) compared with placebo (high certainty).

1 finding from 1 review

Probiotics vs placebo

Adverse events (serious adverse reaction and adverse reaction) · children and adults with CF

Probiotics showed no clear difference in adverse events (serious adverse reaction and adverse reaction) compared with placebo (low certainty).

1 finding from 1 review

Tramadol vs placebo

Number of participants experiencing any serious adverse events · Patients with osteoarthritis of the knee or hip

Tramadol alone may leads to higher number of participants experiencing any serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Losigamone vs placebo

Proportion of participants experiencing adverse events · people with focal epilepsy

Losigamone showed no clear difference in the proportion of participants experiencing any adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Oestrogen in combination with progestogen (sequential or continuous) vs placebo

Withdrawals due to adverse events · women with PMS

It is very uncertain whether oestrogen in combination with progestogen (sequential or continuous) changes withdrawal due to adverse events over 2 to 4 menstrual cycles1 compared with placebo (very low certainty).

1 finding from 1 review

Lidocaine vs placebo or no intervention

Adverse events (AEs; adverse drug reaction): sinus bradycardia · patients with acute myocardial infarction

It is very uncertain whether lidocaine changes adverse events (AEs; adverse drug reaction): sinus bradycardia compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Live zoster vaccine vs placebo

Participants with adverse events Clinical or laboratory criteria · healthy older adults aged ≥ 60 years

Live zoster vaccine probably leads to higher participants with adverse eventsClinical or laboratory criteria compared with placebo (moderate certainty).

1 finding from 1 review

Botulinum toxin type A vs placebo

Adverse events (reported at any time) (2 RCT, 169 participants) · adults with blepharospasm

Botulinum toxin type A showed no clear difference in adverse events (reported at any time) (2 RCT, 169 participants) compared with placebo (low certainty).

1 finding from 1 review

Mepolizumab intravenous (IV) vs placebo

Clinically significant adverse events leading to discontinuation · people with asthma

Mepolizumab intravenous (IV) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (high certainty).

1 finding from 1 review

Reslizumab intravenous (IV) vs placebo

Clinically significant adverse events leading to discontinuation · people with asthma

Reslizumab intravenous (IV) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (high certainty).

1 finding from 1 review

Reslizumab subcutaneous (SC) vs placebo

Clinically significant adverse events leading to discontinuation · people with asthma

Reslizumab subcutaneous (SC) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab subcutaneous (SC) vs placebo

Clinically significant adverse events leading to discontinuation · people with asthma

Benralizumab subcutaneous (SC) leads to higher clinically significant adverse events leading to discontinuation compared with placebo (high certainty).

1 finding from 1 review

Mepolizumab subcutaneous (SC) vs placebo

Clinically significant adverse events leading to discontinuation · people with asthma

Mepolizumab subcutaneous (SC) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (high certainty).

1 finding from 1 review

Donepezil 5 mg vs placebo

Adverse events (all reported adverse events grouped) at 24 weeks · vascular dementia and other vascular cognitive impairments

Donepezil 5 mg showed no clear difference in adverse events (all reported adverse events grouped) at 24 weeks compared with placebo (moderate certainty).

1 finding from 1 review